Therapeutic Insights Into a Case-Control Approach to B-cell Lymphoma 3 (BCL3)-Encoded Protein by Exploring Immune Modulation and Clinical Strategies in Oral Carcinomas
The highest <i>BCL3</i> expression was seen in SCC samples (2.91 ± 0.62), followed by MEC samples (1.87 ± 0.58), while healthy controls showed baseline levels of expression (0.94 ± 0.49). The elevated expression of <i>BCL3</i> is highly correlated with the advanced stage of the tumour, reduced immune infiltration, and multi-modal treatment requirements. Consequently, <i>BCL3</i> appeared to put a modulatory force on the immunity environment of tumours in OC, particularly in SCC cases.
Authors
- Mostafa Ahmed Abdellah Ahmed
- Aysha B. Khalid (ORCID: https://orcid.org/0000-0002-6489-8919)
- Abdul Rehman Khalil Shaikh
- L.M.B.O. Asad
- Shah Mv
- Madeeha Minhas
- Seemi Tanvir
Institutions
- Liaquat University of Medical & Health Sciences (PK)
- COMSATS University Islamabad (PK)
- Rawalpindi Medical University (PK)
- University of the Punjab (PK)
- King Saud bin Abdulaziz University for Health Sciences (SA)
- Frimley Health NHS Foundation Trust (GB)
- University of Health Sciences Lahore (PK)
- Dow University of Health Sciences (PK)
- National University of Medical Sciences (PK)
Publication Details
- Journal
- Cureus
- Published
- 2025-05-06
- DOI
- https://doi.org/10.7759/cureus.83621
- Primary Topic
- Peptidase Inhibition and Analysis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- University of the Punjab